An interventional study of Nerve conduction study and Nerve ultrasound in Diabete Mellitus and Peripheral (Sensorimotor) Diabetic Polyneuropathy, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by Assiut University · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetic Neuropathies with a site in Egypt — 9 open to participants now, 9 under way, none of them phase 3. Diabetic Neuropathies · Egypt.
Among the 31 studies in Diabetic Neuropathies with a site in Egypt, this one is the 7th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 29th registered.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
Browse Diabetic Neuropathies studies →9 of the 31 studies in Diabetic Neuropathies with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 45–60
Ain Shams University · Sites in Egypt
Ages 40–75
Ain Shams University · Sites in Egypt
Ages 45+
Cairo University · Sites in Egypt
Ages 18–70
South Valley University · Sites in Egypt
Ages 40–60
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 3
First in 2015; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Median enrollment 60 across the 22 interventional studies, 65 across the 9 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 31 have an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Assiut University has 4 studies filed under Diabetic Neuropathies — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetic Neuropathies with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07306884Assiut UniversityNeurophysiological, Autonomic, and Sonographic Assessment of Diabetic Peripheral Neuropathy | 2027-01 |
| NCT07036796Ain Shams UniversityEffect of Melatonin in Patients With Diabetic Peripheral Neuropathy | 2027-07-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetic Neuropathies with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diabetic peripheral neuropathy causes pain, sensory loss, and foot risk; multimodal assessment enables earlier diagnosis and improved patient management.
Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, associated with pain, sensory deficits, gait instability, and increased risk of foot ulcers and amputation. Conventional diagnostic methods, such as nerve conduction studies, primarily identify established disease and may overlook early or autonomic involvement. A multimodal assessment integrating neurophysiological, autonomic, and sonographic techniques offers the potential for earlier detection, improved diagnostic accuracy, and optimized patient management.
539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.
This study's planned enrollment of 75 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.
Browse Diabetic Neuropathies studies →Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Diabetic Neuropathies, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18-75 years with type 1 or type 2 diabetes (with or without diabetic peripheral neuropathy), and age and sex-matched healthy controls
Exclusion Criteria:
Diagnostic Test: Nerve conduction study · Diagnostic Test: Nerve ultrasound
Diagnostic Test: Nerve conduction study · Diagnostic Test: Nerve ultrasound · Diagnostic Test: Autonomic assessment
Diagnostic Test: Nerve conduction study · Diagnostic Test: Nerve ultrasound · Diagnostic Test: Autonomic assessment
Nerve conduction studies (NCS) are widely regarded as the gold standard for evaluating large-fiber peripheral nerve function. They measure conduction velocity, latency, and amplitude, providing objective evidence of axonal loss or demyelination. While highly specific, NCS often detect abnormalities only in established diabetic peripheral neuropathy, limiting their sensitivity for early or subclinical disease.
High-resolution ultrasound (HRUS) is a non-invasive imaging tool that allows structural evaluation of peripheral nerves. It can measure cross-sectional area (CSA), visualize fascicular pattern, and detect nerve enlargement or structural abnormalities. In diabetic peripheral neuropathy, HRUS provides complementary information to functional tests and may identify early or subclinical changes.
Autonomic testing provides insight into small-fiber and autonomic nervous system function, often impaired early in diabetic peripheral neuropathy. Heart rate variability (HRV) during deep breathing and postural change is a simple, non-invasive method to detect cardiovascular autonomic dysfunction
Sensitivity of nerve conduction studies for diagnosing diabetic peripheral neuropathy
Percentage of participants with clinically diagnosed diabetic peripheral neuropathy who have abnormal nerve conduction study results (reduced amplitude and/or reduced conduction velocity) at the baseline visit.
Time frame: Baseline (single study visit)
Correlation between tibial nerve cross-sectional area and tibial motor conduction velocity
Correlation coefficient between tibial nerve cross-sectional area measured by high-resolution ultrasound and tibial motor nerve conduction velocity at the baseline visit.
Time frame: Baseline (single study visit)
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.
Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 12 months is close to that.
Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.